These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 33179260)

  • 1. The role and therapeutic implications of PI3K signaling pathway in cancer.
    Leiphrakpam PD; Chowdhury S; Wang J; Black JD; Are C
    J Surg Oncol; 2021 Jan; 123(1):39-41. PubMed ID: 33179260
    [No Abstract]   [Full Text] [Related]  

  • 2. The relation between PI3K/AKT signalling pathway and cancer.
    Noorolyai S; Shajari N; Baghbani E; Sadreddini S; Baradaran B
    Gene; 2019 May; 698():120-128. PubMed ID: 30849534
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combination of PI3K and MEK inhibitors yields durable remission in PDX models of PIK3CA-mutated metaplastic breast cancers.
    Coussy F; El Botty R; Lavigne M; Gu C; Fuhrmann L; Briaux A; de Koning L; Dahmani A; Montaudon E; Morisset L; Huguet L; Sourd L; Painsec P; Chateau-Joubert S; Larcher T; Vacher S; Melaabi S; Salomon AV; Marangoni E; Bieche I
    J Hematol Oncol; 2020 Feb; 13(1):13. PubMed ID: 32087759
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Overcoming acquired resistance to anticancer therapy: focus on the PI3K/AKT/mTOR pathway.
    Burris HA
    Cancer Chemother Pharmacol; 2013 Apr; 71(4):829-42. PubMed ID: 23377372
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting PI3K signalling in cancer: opportunities, challenges and limitations.
    Engelman JA
    Nat Rev Cancer; 2009 Aug; 9(8):550-62. PubMed ID: 19629070
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PI3K/Akt/mTOR inhibitors in cancer: At the bench and bedside.
    Alzahrani AS
    Semin Cancer Biol; 2019 Dec; 59():125-132. PubMed ID: 31323288
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Target-based therapeutic matching in early-phase clinical trials in patients with advanced colorectal cancer and PIK3CA mutations.
    Ganesan P; Janku F; Naing A; Hong DS; Tsimberidou AM; Falchook GS; Wheler JJ; Piha-Paul SA; Fu S; Stepanek VM; Lee JJ; Luthra R; Overman MJ; Kopetz ES; Wolff RA; Kurzrock R
    Mol Cancer Ther; 2013 Dec; 12(12):2857-63. PubMed ID: 24092809
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antitumor Efficacy of the Dual PI3K/mTOR Inhibitor PF-04691502 in a Human Xenograft Tumor Model Derived from Colorectal Cancer Stem Cells Harboring a PIK3CA Mutation.
    Fang DD; Zhang CC; Gu Y; Jani JP; Cao J; Tsaparikos K; Yuan J; Thiel M; Jackson-Fisher A; Zong Q; Lappin PB; Hayashi T; Schwab RB; Wong A; John-Baptiste A; Bagrodia S; Los G; Bender S; Christensen J; Vanarsdale T
    PLoS One; 2013; 8(6):e67258. PubMed ID: 23826249
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combination treatment with a PI3K/Akt/mTOR pathway inhibitor overcomes resistance to anti-HER2 therapy in PIK3CA-mutant HER2-positive breast cancer cells.
    Fujimoto Y; Morita TY; Ohashi A; Haeno H; Hakozaki Y; Fujii M; Kashima Y; Kobayashi SS; Mukohara T
    Sci Rep; 2020 Dec; 10(1):21762. PubMed ID: 33303839
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Dermatological implications of the PI3K pathway].
    Dereure O
    Ann Dermatol Venereol; 2015 Oct; 142(10):622-3. PubMed ID: 26001484
    [No Abstract]   [Full Text] [Related]  

  • 11. Phytochemicals as PI3K/ Akt/ mTOR Inhibitors and Their Role in Breast Cancer Treatment.
    Narayanankutty A
    Recent Pat Anticancer Drug Discov; 2020; 15(3):188-199. PubMed ID: 32914720
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PI3K/AKT/mTOR inhibitors in patients with breast and gynecologic malignancies harboring PIK3CA mutations.
    Janku F; Wheler JJ; Westin SN; Moulder SL; Naing A; Tsimberidou AM; Fu S; Falchook GS; Hong DS; Garrido-Laguna I; Luthra R; Lee JJ; Lu KH; Kurzrock R
    J Clin Oncol; 2012 Mar; 30(8):777-82. PubMed ID: 22271473
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of the PI3K/AKT/mTOR signaling pathway in ovarian cancer: Biological and therapeutic significance.
    Ediriweera MK; Tennekoon KH; Samarakoon SR
    Semin Cancer Biol; 2019 Dec; 59():147-160. PubMed ID: 31128298
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of the PI3K/AKT and mTOR signaling pathways in acute myeloid leukemia.
    Park S; Chapuis N; Tamburini J; Bardet V; Cornillet-Lefebvre P; Willems L; Green A; Mayeux P; Lacombe C; Bouscary D
    Haematologica; 2010 May; 95(5):819-28. PubMed ID: 19951971
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [PI3K-AKT-mTOR pathway inhibitors].
    Cortot A; Armand JP; Soria JC
    Bull Cancer; 2006 Jan; 93(1):19-26. PubMed ID: 16455502
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development of PI3K inhibitors: lessons learned from early clinical trials.
    Rodon J; Dienstmann R; Serra V; Tabernero J
    Nat Rev Clin Oncol; 2013 Mar; 10(3):143-53. PubMed ID: 23400000
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of constitutively activated phosphoinositide 3-kinase/AKT pathway enhances antitumor activity of chemotherapeutic agents in breast cancer susceptibility gene 1-defective breast cancer cells.
    Yi YW; Kang HJ; Kim HJ; Hwang JS; Wang A; Bae I
    Mol Carcinog; 2013 Sep; 52(9):667-75. PubMed ID: 22488590
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Alterations of the p53 and PIK3CA/AKT/mTOR pathways in angiosarcomas: a pattern distinct from other sarcomas with complex genomics.
    Italiano A; Chen CL; Thomas R; Breen M; Bonnet F; Sevenet N; Longy M; Maki RG; Coindre JM; Antonescu CR
    Cancer; 2012 Dec; 118(23):5878-87. PubMed ID: 22648906
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Diverse mechanisms activate the PI 3-kinase/mTOR pathway in melanomas: implications for the use of PI 3-kinase inhibitors to overcome resistance to inhibitors of BRAF and MEK.
    Tran KB; Kolekar S; Jabed A; Jaynes P; Shih JH; Wang Q; Flanagan JU; Rewcastle GW; Baguley BC; Shepherd PR
    BMC Cancer; 2021 Feb; 21(1):136. PubMed ID: 33549048
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PI3King the lock: targeting the PI3K/Akt/mTOR pathway as a novel therapeutic strategy in neuroblastoma.
    King D; Yeomanson D; Bryant HE
    J Pediatr Hematol Oncol; 2015 May; 37(4):245-51. PubMed ID: 25811750
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.